Product logins

Find logins to all Clarivate products below.


Hepatocellular Carcinoma – Epidemiology – Epidemiology Dashboard

Clarivate Epidemiology’s coverage of hepatocellular carcinoma (HCC) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed prevalence and diagnosed incidence of hepatocellular carcinoma (HCC) for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the mature markets and Europe, and 10 years for the other countries we cover.

All forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology’s hepatocellular carcinoma forecast answers the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of hepatocellular carcinoma and the number of new diagnoses of hepatocellular carcinoma?
  • Of all people diagnosed with hepatocellular carcinoma, how many in each country across the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of hepatocellular carcinoma over the forecast period?

In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following hepatocellular carcinoma subpopulations:

  • Diagnosed incident cases
  • Diagnosed early incident cases
  • Diagnosed intermediate incident cases
  • Diagnosed advanced incident cases
  • Diagnosed prevalent population
  • Recurrent incident cases
  • Drug-treatable and drug-treated populations

Note: Coverage may vary by country

Related Market Assessment Reports

Report
Gout – Current Treatment – Treatment Algorithms: Claims Data Analysis – Gout (US)
Gout, a form of inflammatory arthritis, arises due to the persistent elevation of serum uric acid (sUA) levels. The condition manifests through sudden and intense gout flares, causing significant…
Report
Gene Therapy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Approximately 80% of rare diseases have a genetic etiology. Gene therapies have the potential to transform the treatment of rare diseases and, in some cases, provide a functional cure. The pipeline…
Report
Epilepsy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Epilepsy is a complex neurological disorder marked by recurrent seizures, affecting approximately 4.7 million people across the major markets, as reported by Clarivate Epidemiology. Given epilepsy…
Report
Dry Eye – Landscape & Forecast – Disease Landscape & Forecast (G7)
Dry eye disease (DED) is characterized by the loss of tear film homeostasis, caused by the inadequate production or the rapid evaporation of tears. The DED market is evolving rapidly, driven by…
Report
Asthma – Landscape & Forecast – Disease Landscape & Forecast (G7)
The asthma therapy market consists of many well-established drugs, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s Spiriva…